Russian Federation (RU)

VLBI Scrutiny of a New Neutrino-Blazar Multiwavelength-Flare Coincidence (2023) Eppel F, Kadler M, Ros E, Rösch F, Heβdörfer J, Benke P, Edwards PG, et al. Conference contribution Developments and results in the context of the JEM-EUSO program obtained with the ESAF simulation and analysis framework (2023) Abe S, Adams JH, Allard D, Alldredge P, Anchordoqui L, Anzalone A, Arnone E, et al. Journal article Enhancing Electroretinogram Classification with Multi-Wavelet Analysis and Visual Transformer (2023) Kulyabin M, Zhdanov A, Dolganov A, Ronkin M, Borisov V, Maier A Journal article, Online publication Diagnostic criteria for Buerger's disease: International Consensus of VAS - European Independent Foundation in Angiology/Vascular Medicine (2023) Fazeli B, Poredos P, Kozak M, Pecsvarady Z, Catalano M, Al Salman MM, Altarazi L, et al. Journal article Search for two-neutrino double-beta decay of 136Xe to the excited state of 136Ba with the complete EXO-200 dataset (2023) Al Kharusi S, Anton G, Badhrees I, Barbeau PS, Beck D, Belov V, Bhatta T, et al. Journal article Evaluation of Prognostic Parameters to Identify Aggressive Penile Carcinomas (2023) Mink JN, Khalmurzaev O, Pryalukhin A, Geppert CI, Lohse S, Bende K, Lobo J, et al. Journal article An integrated online radioassay data storage and analytics tool for nEXO (2023) Tsang RH, Piepke A, Al Kharusi S, Angelico E, Arnquist IJ, Atencio A, Badhrees I, et al. Journal article 3D-Shaped Binders of Unfolded Proteins Inducing Cancer Cell-Specific Endoplasmic Reticulum Stress In Vitro and In Vivo (2023) Klemt I, Varzatskii O, Selin R, Vakarov S, Kovalska VB, Bila G, Bilyy R, et al. Journal article High-temperature mechanical properties of MAX-phase based functionally graded laminated composites fabricated from preceramic papers (2023) Krotkevich DG, Kashkarov EB, Krinitsyn MG, Travitzky N Conference contribution Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study (2023) Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, Vasiliev A, et al. Journal article